Better Medicine, Together
Most trusted partner in therapeutic drug discovery with fully integrated services and cutting-edge platform technologies across multiple modalities
Empowering drug discovery through AI/ML-driven innovation and integrated solutions
We support partners and collaborators with AI-enabled discovery platforms, foundational technologies, and fully integrated wet and dry lab services. With expertise across multiple modalities, we confidently tackle challenging programs and deliver success backed by years of scientific and operational excellence.
Discover our platforms and services
AI/ML
Accelerating discovery with Alloy’s integrated AI/ML
Alloy Therapeutics embeds AI/ML directly into the core of our discovery and development platform, uniting predictive modeling with a global wet-lab engine to drive real biological outcomes. Trained on one of the industry’s largest proprietary experimental datasets, our models shorten design cycles, improve prediction accuracy, and enable teams to rapidly move from concept to human data with speed, precision, and capital efficiency.
Antibodies & Bispecifics
End-to-end antibody and bispecific discovery services using our proprietary platforms
Our platforms and fully integrated services streamline the path to IND for your monoclonal and bispecific programs. We offer cutting-edge in vivo discovery platforms combined with end-to-end services across monoclonal discovery, bispecific engineering, and lead optimization to quickly and efficiently deliver high-quality, de-risked therapeutic candidates.
TCR Mimics
Unlock new targets with TCRms
TCRm antibodies mimic the function of T-cell receptors by targeting intracellular peptides presented on cell surface MHC complexes (pMHC), opening up a wide range of intracellular targets in oncology and infectious disease. Keyway™ TCRm discovery is the first fully integrated platform and service, combining our world-class antibody discovery expertise with the pioneers of TCR Therapeutics.
Genetic medicines
Empowering breakthroughs with Alloy’s antisense platform
Alloy Therapeutics offers foundational technologies and discovery capabilities that address the therapeutic index and delivery challenges that have historically limited the promise of ASO drug candidates. Collaborate with us to transform your existing sequences or discover de novo molecules in our proprietary Anticlastic™ antisense format, a transiently cyclized structure designed for improved potency, safety, and scalability.
Cell Therapies
Next-gen cell therapies designed for speed, safety, and scale
A versatile T cell platform delivers off-the-shelf cell therapies with enhanced safety, potency, and scalability. Engineered with γδTCRs, customizable CARs and armoring technologies, built on Alloy’s hypoimmune iPSC platform, it enables rapid innovation, reduces risks such as GvHD and host rejection, lowers manufacturing costs, and accelerates the clinical development of next-generation therapies.
Collaboration among scientists, competition against disease
We collaborate with our partners to leverage the full potential of our technology and services, acting as an innovation engine for the drug discovery industry.
